The use of an obstetric balloon as a pelvic spacer in preventing empty pelvis syndrome after total pelvic exenteration in rectal cancers – A prospective safety and efficacy study for the Bakri balloon

• Published in: Colorectal disease 2023-04, Vol.25 (4), p.616-623
• Main Authors: Kazi, Mufaddal, Desouza, Ashwin, Bankar, Sanket, Jajoo, Bhushan, Dohale, Sayali, Vadodaria, Divya, Ghadi, Aayushi, Ghandade, Netra, Vasudevan, Lakshanya, Nashikkar, Chaitali, Saklani, Avanish
• Format: Article
• Language: English
• Subjects: Bakri balloon; Balloons; empty pelvis syndrome; Female; Humans; Morbidity; obstetric balloon; Obstetrics; obstruction; pelvic exenterations; pelvic spacer; Pelvis; Pelvis - surgery; Perineum; Postpartum Hemorrhage - etiology; Postpartum Hemorrhage - prevention & control; Pregnancy; Prospective Studies; Rectal Neoplasms - therapy; Rectum; Retrospective Studies; Uterine Balloon Tamponade - adverse effects
• ISSN: 1462-8910; 1463-1318
• DOI: 10.1111/codi.16424

Aim Empty pelvis syndrome (EPS) is a source of considerable morbidity following total pelvic exenteration. None of the available methods have been universally successful in mitigating this problem. The aim of this work was to evaluate the safety and efficacy of the obstetric Bakri balloon in preventing empty pelvis syndrome. Method This study was a combined prospective and retrospective study of all total pelvic exenterations for rectal cancers from a single institution performed between October 2013 and May 2022. Since December 2019 the Bakri balloon was used in all patients who provided consent. EPS within 90 days was the primary end point, and included bowel obstruction, pelvic collection and entero‐perineal fistula. Comparison with those patients who did not have a Bakri balloon was performed. Results Seventy‐five patients with a Bakri balloon were compared with 96 patients without a balloon placed after pelvic exenteration. No patient experienced an untoward complication from balloon deployment. The incidence of EPS was 13.3% and 22.9% in the Bakri and no Bakri cohorts, respectively (p = 0.110). Every component of EPS was proportionally lower, without statistical significance. Based on point estimates, the number needed to treat to prevent EPS using the Bakri balloon was 10. Conclusions Use of the Bakri balloon was safe without serious adverse events. The incidence of EPS after total pelvic exenteration was not statistically different with the use of the Bakri balloon despite a 9.6% reduction. A larger comparative study is needed to evaluate the efficacy of the balloon.